Incyte Corp (INCY)
$85.56 0.45 (0.53%)
15:38 EDT INCY Stock Quote Delayed 20 Minutes
Previous Close $85.11
Market Cap 18.14B
PE Ratio -112.58
Volume (Avg. Vol.) 1.76M
Day's Range 85.13 - 87.85
52-Week Range 62.48 - 96.79
Dividend & Yield N/A (N/A)
INCY Stock Predictions, Articles, and Incyte Corp News
- From InvestorPlace
- From the Web
Stocks were hit for what feels like the first time in a long time. Here's what happened in the stock market today.
Incyte (INCY) news for Friday about a recent clinical trial failing to meet its endpoints has INCY stock taking a beating.
With FDA Breakthrough Therapy designations and robust drug pipelines, these biotech companies are all stocks to buy for 2020.
With August now upon us, not only is the overbought market vulnerable to profit-taking, the calendar is working against stocks as well. One average, the market loses ground rather than gains ground in the month of August, as well as for September.
Trump says that Facebook and Alphabet should be sued, while Micron surged on earnings. Semiconductors got a big boost in the Nasdaq today as well.
PayPal, Slack, and chip stocks like AMD and Nvidia, Micron and Nio were all big movers in the Nasdaq today. Get the scoop, now.
Incyte, Whirlpool and Baxter are just some of the hot stocks to buy here as a means of shrugging off the summer's looming lethargy.
Biotech stocks fell sharply in the last few weeks, mostly on no new news. This drop may have created an entry point for investors.
The stock charts of INCY, LYB and FMC are going to start this week's hump-day at a precipice. Here are the numbers to know.
The stock charts of COG, INCY and SRE are worth a closer technical look at the midpoint of the trading week.
The stock charts of PFE, INCY and MGM are finally making good on previously-suggested promise.
The stock charts of INCY, ABT and SLB are set to end the week on a more definitive, trade-worthy footing than most other names.
The stock charts of SLG, INCY and ETR are shaping up as the best trading bets as the new week kicks off.
Incyte (INCY) was falling hard on Friday following news of a failed Phase 3 drug trial for its melanoma drug epacadostat.
If you’re itching to buy, avoid these stocks at all costs. Here's what makes them stocks to sell for all wise investors.
Here are the 10 stock picks top investors are betting on right now. We take a look at how investors are trading these stocks -- and whether the Street agrees.
From Simply Wall St
Broadly speaking, profitable businesses are less risky than unprofitable ones. Having said that, sometimes statutory profit levels are not a good guide to ongoing profitability, because some short term one-off<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/we-think-incytes-nasdaqincy-statutory-profit-might-understate-its-earnings-potential-2/">Read More...</a></div>
From Analyst Ratings
In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Incyte (INCY – Research Report), with a price target of $90.00. The company’s shares closed last Monday at $85.11. According to TipRanks.com, Olson ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -14.7%
From Market News Video
Holiday Market Closures, Jobless Claims Data, Consumer Sentiment, and More for Investors to Watch This Week
From Seeking Alpha
Navellier RatingsPowered by Portfolio Grader